We present four different pediatric cases of FLT3-ITD-positive AML and hyperleukocytosis that were treated with sorafenib during their cytoreductive prephase or—in one case—after inadequate response to the cytoreductive prephase in parallel to induction. This evidence concerns the gene FLT3 and acute myeloid leukemia.